Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2013
This article has no abstract
Epistemonikos ID: 76d8fb572f8e0362f0473f1135d494d917470a23
First added on: Feb 05, 2025